Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chagas Disease | 12 | 2026 | 314 | 3.930 |
Why?
|
| Trypanosoma cruzi | 10 | 2026 | 256 | 3.060 |
Why?
|
| HIV Infections | 9 | 2025 | 2044 | 2.170 |
Why?
|
| Immunocompromised Host | 2 | 2024 | 313 | 1.450 |
Why?
|
| Chagas Cardiomyopathy | 6 | 2026 | 51 | 1.410 |
Why?
|
| Emigrants and Immigrants | 3 | 2025 | 169 | 1.300 |
Why?
|
| Strongyloidiasis | 3 | 2025 | 51 | 1.100 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 368 | 1.010 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 380 | 1.010 |
Why?
|
| Papillomavirus Infections | 2 | 2021 | 388 | 1.000 |
Why?
|
| Hospitals, Public | 1 | 2026 | 51 | 0.940 |
Why?
|
| Neurocysticercosis | 1 | 2026 | 27 | 0.940 |
Why?
|
| Pandemics | 4 | 2023 | 1169 | 0.900 |
Why?
|
| Strongyloides stercoralis | 2 | 2025 | 24 | 0.890 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 702 | 0.810 |
Why?
|
| Teaching Rounds | 1 | 2023 | 30 | 0.780 |
Why?
|
| Betacoronavirus | 3 | 2020 | 288 | 0.760 |
Why?
|
| Veterans | 3 | 2024 | 1803 | 0.710 |
Why?
|
| Herpesvirus 8, Human | 1 | 2021 | 47 | 0.680 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2021 | 41 | 0.680 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 46 | 0.660 |
Why?
|
| Contact Tracing | 1 | 2021 | 57 | 0.660 |
Why?
|
| Health Communication | 1 | 2020 | 31 | 0.650 |
Why?
|
| Immune Tolerance | 1 | 2021 | 153 | 0.650 |
Why?
|
| Helminthiasis | 1 | 2021 | 83 | 0.640 |
Why?
|
| Herpesviridae Infections | 1 | 2021 | 140 | 0.630 |
Why?
|
| Viremia | 1 | 2020 | 132 | 0.620 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 134 | 0.580 |
Why?
|
| Antibodies, Protozoan | 5 | 2026 | 99 | 0.570 |
Why?
|
| Organ Transplantation | 1 | 2020 | 173 | 0.560 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 153 | 0.560 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 260 | 0.550 |
Why?
|
| HIV | 3 | 2024 | 178 | 0.520 |
Why?
|
| Merozoite Surface Protein 1 | 3 | 2012 | 11 | 0.520 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 354 | 0.500 |
Why?
|
| Malaria, Falciparum | 3 | 2012 | 67 | 0.500 |
Why?
|
| United States | 11 | 2025 | 11867 | 0.490 |
Why?
|
| Plasmodium falciparum | 3 | 2012 | 93 | 0.490 |
Why?
|
| Humans | 43 | 2026 | 132194 | 0.470 |
Why?
|
| Vaccination | 1 | 2020 | 1041 | 0.450 |
Why?
|
| Immunologic Memory | 2 | 2012 | 197 | 0.400 |
Why?
|
| Antigens, Protozoan | 3 | 2026 | 78 | 0.390 |
Why?
|
| Internship and Residency | 1 | 2023 | 1220 | 0.390 |
Why?
|
| Endemic Diseases | 3 | 2026 | 61 | 0.370 |
Why?
|
| Pacemaker, Artificial | 1 | 2014 | 195 | 0.360 |
Why?
|
| Papillomaviridae | 2 | 2021 | 179 | 0.320 |
Why?
|
| Female | 23 | 2026 | 71459 | 0.310 |
Why?
|
| Rituximab | 2 | 2021 | 175 | 0.300 |
Why?
|
| Protozoan Proteins | 2 | 2026 | 133 | 0.300 |
Why?
|
| Adult | 19 | 2026 | 31771 | 0.290 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 3858 | 0.280 |
Why?
|
| Bolivia | 7 | 2017 | 13 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2025 | 792 | 0.280 |
Why?
|
| Middle Aged | 16 | 2026 | 28963 | 0.280 |
Why?
|
| Peru | 6 | 2025 | 56 | 0.270 |
Why?
|
| Immunoglobulin G | 4 | 2022 | 796 | 0.250 |
Why?
|
| Biomarkers | 3 | 2015 | 3429 | 0.250 |
Why?
|
| Leishmania mexicana | 1 | 2026 | 6 | 0.250 |
Why?
|
| Genome, Protozoan | 1 | 2026 | 26 | 0.240 |
Why?
|
| Taenia solium | 1 | 2026 | 13 | 0.240 |
Why?
|
| Neoplasms | 1 | 2021 | 2968 | 0.240 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2026 | 51 | 0.240 |
Why?
|
| Neuraminidase | 1 | 2026 | 40 | 0.240 |
Why?
|
| Strongyloides | 1 | 2025 | 22 | 0.230 |
Why?
|
| Mobile Health Units | 1 | 2025 | 29 | 0.230 |
Why?
|
| Retrospective Studies | 5 | 2026 | 17772 | 0.220 |
Why?
|
| Insecticides | 2 | 2017 | 47 | 0.220 |
Why?
|
| Male | 18 | 2026 | 65494 | 0.220 |
Why?
|
| Trypanocidal Agents | 1 | 2024 | 33 | 0.210 |
Why?
|
| Penile Neoplasms | 1 | 2024 | 37 | 0.210 |
Why?
|
| Glycoproteins | 1 | 2026 | 348 | 0.200 |
Why?
|
| Prevalence | 7 | 2026 | 2706 | 0.200 |
Why?
|
| Texas | 3 | 2026 | 3657 | 0.190 |
Why?
|
| Risk Factors | 6 | 2025 | 11041 | 0.190 |
Why?
|
| Quality of Health Care | 1 | 2026 | 413 | 0.190 |
Why?
|
| Neuroimaging | 1 | 2026 | 406 | 0.190 |
Why?
|
| Peptides | 1 | 2026 | 725 | 0.190 |
Why?
|
| Noncommunicable Diseases | 1 | 2022 | 21 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2020 | 209 | 0.190 |
Why?
|
| Coinfection | 1 | 2024 | 192 | 0.180 |
Why?
|
| Internal Medicine | 1 | 2023 | 124 | 0.180 |
Why?
|
| Young Adult | 9 | 2025 | 10131 | 0.180 |
Why?
|
| Aged | 10 | 2026 | 21304 | 0.180 |
Why?
|
| Helminths | 1 | 2022 | 51 | 0.180 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 199 | 0.170 |
Why?
|
| Kava | 1 | 2020 | 8 | 0.170 |
Why?
|
| Unemployment | 1 | 2020 | 23 | 0.160 |
Why?
|
| Data Accuracy | 1 | 2020 | 31 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2021 | 192 | 0.160 |
Why?
|
| Malaria Vaccines | 2 | 2012 | 25 | 0.160 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 123 | 0.160 |
Why?
|
| Adolescent | 11 | 2025 | 21021 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2020 | 88 | 0.160 |
Why?
|
| Housing | 1 | 2020 | 73 | 0.160 |
Why?
|
| Animals | 9 | 2026 | 34291 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 666 | 0.160 |
Why?
|
| Eosinophils | 1 | 2020 | 127 | 0.160 |
Why?
|
| Doxorubicin | 1 | 2021 | 301 | 0.150 |
Why?
|
| Seroepidemiologic Studies | 4 | 2026 | 167 | 0.150 |
Why?
|
| Food Supply | 1 | 2020 | 91 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2024 | 1240 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2021 | 193 | 0.150 |
Why?
|
| Mass Screening | 1 | 2025 | 821 | 0.150 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 78 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 131 | 0.150 |
Why?
|
| Fatal Outcome | 1 | 2020 | 364 | 0.150 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 146 | 0.150 |
Why?
|
| Bone Density | 1 | 2022 | 362 | 0.150 |
Why?
|
| Developing Countries | 1 | 2021 | 306 | 0.150 |
Why?
|
| Inpatients | 1 | 2023 | 544 | 0.150 |
Why?
|
| Public Health | 1 | 2021 | 276 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 190 | 0.140 |
Why?
|
| B-Lymphocytes | 2 | 2012 | 511 | 0.140 |
Why?
|
| Syndrome | 1 | 2021 | 1170 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2026 | 2130 | 0.140 |
Why?
|
| Health Policy | 1 | 2020 | 226 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1173 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 6935 | 0.130 |
Why?
|
| Pyrethrins | 1 | 2017 | 9 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 896 | 0.130 |
Why?
|
| Insecticide Resistance | 1 | 2017 | 30 | 0.130 |
Why?
|
| Poverty | 1 | 2020 | 455 | 0.130 |
Why?
|
| Triatoma | 1 | 2017 | 30 | 0.120 |
Why?
|
| Insect Proteins | 1 | 2017 | 99 | 0.120 |
Why?
|
| Child, Preschool | 9 | 2026 | 15103 | 0.120 |
Why?
|
| Incidence | 2 | 2024 | 3358 | 0.120 |
Why?
|
| Nitriles | 1 | 2017 | 165 | 0.120 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2015 | 326 | 0.120 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2015 | 21 | 0.120 |
Why?
|
| Ventricular Premature Complexes | 1 | 2015 | 17 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1916 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2021 | 814 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2015 | 88 | 0.110 |
Why?
|
| Electrocardiography | 3 | 2015 | 984 | 0.110 |
Why?
|
| Antibodies, Helminth | 2 | 2025 | 131 | 0.110 |
Why?
|
| Bundle-Branch Block | 1 | 2015 | 41 | 0.110 |
Why?
|
| Atrioventricular Block | 1 | 2015 | 46 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 506 | 0.110 |
Why?
|
| Chromatography, Affinity | 1 | 2014 | 53 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2015 | 696 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2026 | 3939 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2020 | 703 | 0.100 |
Why?
|
| Insect Control | 1 | 2013 | 11 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1503 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 1274 | 0.100 |
Why?
|
| Stroke Volume | 1 | 2015 | 532 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 763 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 359 | 0.090 |
Why?
|
| Child | 10 | 2025 | 26383 | 0.090 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2012 | 5 | 0.090 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 18 | 0.090 |
Why?
|
| Antigens, CD19 | 1 | 2012 | 191 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 518 | 0.080 |
Why?
|
| Global Health | 1 | 2014 | 634 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2014 | 561 | 0.070 |
Why?
|
| Psychodidae | 1 | 2026 | 14 | 0.060 |
Why?
|
| Central America | 1 | 2026 | 21 | 0.060 |
Why?
|
| South America | 1 | 2026 | 44 | 0.060 |
Why?
|
| Mexico | 1 | 2026 | 197 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 2015 | 11 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2025 | 228 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2015 | 39 | 0.060 |
Why?
|
| Infant | 5 | 2025 | 13356 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 139 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1617 | 0.050 |
Why?
|
| Antiparasitic Agents | 1 | 2024 | 28 | 0.050 |
Why?
|
| Obesity | 1 | 2015 | 2395 | 0.050 |
Why?
|
| Rural Population | 2 | 2017 | 262 | 0.050 |
Why?
|
| California | 1 | 2024 | 128 | 0.050 |
Why?
|
| Phylogeny | 1 | 2026 | 717 | 0.050 |
Why?
|
| Blood Donors | 1 | 2022 | 56 | 0.050 |
Why?
|
| Feces | 1 | 2025 | 725 | 0.040 |
Why?
|
| Morbidity | 1 | 2022 | 262 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2026 | 1030 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2022 | 291 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 534 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Esterases | 1 | 2017 | 12 | 0.030 |
Why?
|
| Nymph | 1 | 2017 | 14 | 0.030 |
Why?
|
| Pregnancy | 2 | 2024 | 7604 | 0.030 |
Why?
|
| Voltage-Gated Sodium Channels | 1 | 2017 | 13 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2026 | 2873 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2017 | 112 | 0.030 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 12 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 93 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2015 | 146 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3721 | 0.030 |
Why?
|
| Serum | 1 | 2014 | 45 | 0.030 |
Why?
|
| Troponin I | 1 | 2015 | 123 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2995 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8615 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 625 | 0.020 |
Why?
|
| Overweight | 1 | 2015 | 379 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 4078 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1412 | 0.020 |
Why?
|
| Mali | 1 | 2011 | 14 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 325 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2011 | 121 | 0.020 |
Why?
|
| Echocardiography | 1 | 2015 | 1140 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2144 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 1697 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2011 | 418 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2869 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 777 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 3098 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1484 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5284 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 5127 | 0.010 |
Why?
|
| Prognosis | 1 | 2015 | 4965 | 0.010 |
Why?
|
| Alleles | 1 | 2010 | 1709 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2656 | 0.010 |
Why?
|